Q2 2023 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2023-08-14 · accession 0001104659-23-091264
$709.3M
Reported value
17
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $168.5M | 23.8% | 2,344,980 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $121.6M | 17.1% | 2,884,492 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $113.8M | 16.0% | 6,029,592 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $43.4M | 6.11% | 2,124,625 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $42.1M | 5.94% | 3,558,975 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $39.0M | 5.50% | 1,482,405 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $32.6M | 4.59% | 1,369,623 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $28.7M | 4.04% | 73,526 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $24.1M | 3.40% | 1,416,998 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $17.9M | 2.52% | 2,040,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $15.8M | 2.23% | 1,901,397 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $13.7M | 1.93% | 1,985,245 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES SA | $13.4M | 1.89% | 7,064,964 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $12.4M | 1.75% | 5,190,360 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $9.9M | 1.40% | 704,459 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $8.1M | 1.14% | 381,939 | Common | SOLE |
| 00773J103 | — | AEGLEA BIOTHERAPEUTICS INC | $4.3M | 0.60% | 9,460,540 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.